These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 24037724)

  • 1. CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT.
    Schmidt-Hieber M; Labopin M; Beelen D; Volin L; Ehninger G; Finke J; Socié G; Schwerdtfeger R; Kröger N; Ganser A; Niederwieser D; Polge E; Blau IW; Mohty M
    Blood; 2013 Nov; 122(19):3359-64. PubMed ID: 24037724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic impact of the cytomegalovirus serostatus in patients with chronic hematological malignancies after allogeneic hematopoietic stem cell transplantation: a report from the Infectious Diseases Working Party of EBMT.
    Schmidt-Hieber M; Tridello G; Ljungman P; Mikulska M; Knelange N; Blaise D; Socié G; Volin L; Blijlevens N; Fegueux N; Yakoub-Agha I; Forcade E; Maertens J; Chevallier P; Passweg J; Cornelissen J; Russell N; Craddock C; Bourhis JH; Marchand T; Reményi P; Cahn JY; Michallet M; Montoto S; Kröger N; Glaß B; Styczynski J
    Ann Hematol; 2019 Jul; 98(7):1755-1763. PubMed ID: 30993417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Donor Epstein-Barr Virus Serostatus on the Incidence of Graft-Versus-Host Disease in Patients With Acute Leukemia After Hematopoietic Stem-Cell Transplantation: A Study From the Acute Leukemia and Infectious Diseases Working Parties of the European Society for Blood and Marrow Transplantation.
    Styczynski J; Tridello G; Gil L; Ljungman P; Hoek J; Iacobelli S; Ward KN; Cordonnier C; Einsele H; Socie G; Milpied N; Veelken H; Chevallier P; Yakoub-Agha I; Maertens J; Blaise D; Cornelissen J; Michallet M; Daguindau E; Petersen E; Passweg J; Greinix H; Duarte RF; Kröger N; Dreger P; Mohty M; Nagler A; Cesaro S
    J Clin Oncol; 2016 Jul; 34(19):2212-20. PubMed ID: 27091716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Graft-versus-leukaemia activity associated with CMV-seropositive donor, post-transplant CMV infection, young donor age and chronic graft-versus-host disease in bone marrow allograft recipients. The Nordic Bone Marrow Transplantation Group.
    Jacobsen N; Badsberg JH; Lönnqvist B; Ringdén O; Volin L; Rajantie J; Nikoskelainen J; Keiding N
    Bone Marrow Transplant; 1990 Jun; 5(6):413-8. PubMed ID: 2164434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia.
    Green ML; Leisenring WM; Xie H; Walter RB; Mielcarek M; Sandmaier BM; Riddell SR; Boeckh M
    Blood; 2013 Aug; 122(7):1316-24. PubMed ID: 23744585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Donor cytomegalovirus seropositivity and the risk of leukemic relapse after reduced-intensity transplants.
    Nachbaur D; Clausen J; Kircher B
    Eur J Haematol; 2006 May; 76(5):414-9. PubMed ID: 16480430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment-related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T-cell depletion with anti-thymocyte globulin.
    Kröger N; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Schafhausen P; Jaburg N; Löliger C; Schäfer P; Hinke A; Zander AR
    Br J Haematol; 2001 Jun; 113(4):1060-71. PubMed ID: 11442503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mycophenolate-based graft versus host disease prophylaxis is not inferior to methotrexate in myeloablative-related donor stem cell transplantation.
    Hamad N; Shanavas M; Michelis FV; Uhm J; Gupta V; Seftel M; Kuruvilla J; Lipton JH; Messner HA; Kim DD
    Am J Hematol; 2015 May; 90(5):392-9. PubMed ID: 25615933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Donor and recipient CMV serostatus and outcome of pediatric allogeneic HSCT for acute leukemia in the era of CMV-preemptive therapy.
    Behrendt CE; Rosenthal J; Bolotin E; Nakamura R; Zaia J; Forman SJ
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):54-60. PubMed ID: 19135943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence, risk factors, and outcome of cytomegalovirus viremia and gastroenteritis in patients with gastrointestinal graft-versus-host disease.
    Bhutani D; Dyson G; Manasa R; Deol A; Ratanatharathorn V; Ayash L; Abidi M; Lum LG; Al-Kadhimi Z; Uberti JP
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):159-64. PubMed ID: 25445637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct clinical features of infectious complications in adult T cell leukemia/lymphoma patients after allogeneic hematopoietic stem cell transplantation: a retrospective analysis in the Nagasaki transplant group.
    Itonaga H; Taguchi J; Fukushima T; Tsushima H; Sato S; Ando K; Sawayama Y; Matsuo E; Yamasaki R; Onimaru Y; Imanishi D; Imaizumi Y; Yoshida S; Hata T; Moriuchi Y; Honda S; Miyazaki Y
    Biol Blood Marrow Transplant; 2013 Apr; 19(4):607-15. PubMed ID: 23333533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant.
    Ghobadi A; Milton DR; Gowda L; Rondon G; Chemaly RF; Hamdi A; Alousi A; Afrough A; Oran B; Ciurea S; Kebriaei P; Popat UR; Qazilbash MH; Shpall EJ; Champlin RE; Bashir Q
    Curr Res Transl Med; 2019 May; 67(2):51-55. PubMed ID: 30683577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Haploidentical allogeneic hematopoietic stem cell transplantation increases the risk of cytomegalovirus infection in adult patients with acute leukemia.
    Lin CH; Su YJ; Hsu CY; Wang PN; Teng CJ
    Transpl Infect Dis; 2019 Aug; 21(4):e13096. PubMed ID: 31004545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early CMV replication and subsequent chronic GVHD have a significant anti-leukemic effect after allogeneic HSCT in acute myeloid leukemia.
    Jang JE; Kim SJ; Cheong JW; Hyun SY; Kim YD; Kim YR; Kim JS; Min YH
    Ann Hematol; 2015 Feb; 94(2):275-82. PubMed ID: 25135450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of cytomegalovirus replication and cytomegalovirus serostatus on the outcome of patients with B cell lymphoma after allogeneic stem cell transplantation.
    Mariotti J; Maura F; Spina F; Roncari L; Dodero A; Farina L; Montefusco V; Carniti C; Sarina B; Patriarca F; Rambaldi A; Onida F; Olivieri A; Zallio F; Corradini P
    Biol Blood Marrow Transplant; 2014 Jun; 20(6):885-90. PubMed ID: 24583412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
    George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
    Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of early CMV reactivation in cord blood stem cell recipients in the current era.
    Ramanathan M; Teira P; Battiwalla M; Barrett J; Ahn KW; Chen M; Green J; Laughlin M; Lazarus HM; Marks D; Saad A; Seftel M; Saber W; Savani B; Waller EK; Wingard J; Auletta JJ; Lindemans CA; Boeckh M; Riches ML
    Bone Marrow Transplant; 2016 Aug; 51(8):1113-20. PubMed ID: 27042847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for cytomegalovirus reactivation after CD6+ T-cell-depleted allogeneic bone marrow transplantation.
    Lin TS; Zahrieh D; Weller E; Alyea EP; Antin JH; Soiffer RJ
    Transplantation; 2002 Jul; 74(1):49-54. PubMed ID: 12134098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years-a report from the EBMT acute leukemia working party.
    Rubio MT; Savani BN; Labopin M; Polge E; Niederwieser D; Ganser A; Schwerdtfeger R; Ehninger G; Finke J; Renate A; Craddock C; Kröger N; Hallek M; Jindra P; Mohty M; Nagler A
    J Hematol Oncol; 2016 Aug; 9(1):65. PubMed ID: 27488518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.